Could a new pill beat the standard for gout? large trial underway

NCT ID NCT07414394

Recruiting now Disease control Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a new drug, tigulixostat, is better than the standard gout medication febuxostat at lowering uric acid levels in Chinese adults with gout. About 600 participants will take one of the two drugs for 24 weeks, then switch to tigulixostat for another 28 weeks. The study tracks uric acid levels, gout attacks, kidney function, and quality of life over a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tigulixostat (also called IBI128) and febuxostat
What this could lead to: If tigulixostat works better than febuxostat, it could offer a new, more effective option for controlling gout by lowering uric acid levels.
What could go wrong: This is a Phase 3 trial, but it only includes Chinese adults, so results may not apply to other groups. Gout is a chronic condition, so this treatment aims to control it, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT

Contacts and locations

Locations

Shanghai Fudan University HuaShan Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.